Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Akebia Therapeutics Stock Quote

Akebia Therapeutics (NASDAQ: AKBA)

$1.39
(-4.8%)
-$0.07
Price as of April 15, 2024, 4:00 p.m. ET

Akebia Therapeutics Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
AKBA +121.34% -79.91% -27.46% -95%
S&P +23.57% +76.22% +11.98% +170%

Akebia Therapeutics Company Info

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.